Literature DB >> 29149610

First Approved Kinase Inhibitor for AML.

John E J Rasko1, Timothy P Hughes2.   

Abstract

Activating mutations of FLT3 occur in about 30% of acute myeloid leukemia (AML) cases and are associated with relapse and poor prognosis. Midostaurin is the first drug approved for AML since 2000, and the first multi-kinase inhibitor approved for the FLT3-mutant subtype. To view this Bench to Bedside, open or download the PDF.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29149610     DOI： 10.1016/j.cell.2017.11.007

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  5 in total

1.  The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.

Authors:  Sung-Han Hsiao; Sabrina Lusvarghi; Yang-Hui Huang; Suresh V Ambudkar; Sheng-Chieh Hsu; Chung-Pu Wu
Journal:  Cancer Lett       Date:  2019-01-11       Impact factor: 8.679

Review 2.  Carbohydrate-based drugs launched during 2000-2021.

Authors:  Xin Cao; Xiaojing Du; Heng Jiao; Quanlin An; Ruoxue Chen; Pengfei Fang; Jing Wang; Biao Yu
Journal:  Acta Pharm Sin B       Date:  2022-05-23       Impact factor: 14.903

Review 3.  Putative role of natural products as Protein Kinase C modulator in different disease conditions.

Authors:  Rishi Kant Singh; Sanjay Kumar; Munendra Singh Tomar; Praveen Kumar Verma; Amit Kumar; Sandeep Kumar; Naveen Kumar; Jai Prakash Singh; Arbind Acharya
Journal:  Daru       Date:  2021-07-03       Impact factor: 4.088

4.  Precursor-Directed Generation of Indolocarbazoles with Topoisomerase IIα Inhibitory Activity.

Authors:  Cong Wang; Adeep Monger; Liping Wang; Peng Fu; Pawinee Piyachaturawat; Arthit Chairoungdua; Weiming Zhu
Journal:  Mar Drugs       Date:  2018-05-17       Impact factor: 5.118

5.  Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia.

Authors:  Katrin Schranz; Max Hubmann; Egor Harin; Sebastian Vosberg; Tobias Herold; Klaus H Metzeler; Maja Rothenberg-Thurley; Hanna Janke; Kathrin Bräundl; Bianka Ksienzyk; Aarif M N Batcha; Sebastian Schaaf; Stephanie Schneider; Stefan K Bohlander; Dennis Görlich; Wolfgang E Berdel; Bernhard J Wörmann; Jan Braess; Stefan Krebs; Wolfgang Hiddemann; Ulrich Mansmann; Karsten Spiekermann; Philipp A Greif
Journal:  Oncotarget       Date:  2018-07-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.